Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

By Yanqiao Zhang, F. Lee, G. Barrera, Hans Lee, Charisse Vales, F. Gonzalez, T. Willson, P. Edwards. Proceedings of the National Academy of Sciences of the United States of America, 2006

939 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/163ec1af0feb9b6186a641f25c18f76f03e99fdb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Calkin
2. P. Tontonoz
3. G. Svegliati-Baroni
4. Harry Sokol
5. Bart Staels
6. Johan Auwerx
7. F. Marra
8. G. Brent

In Oncology

1. P. Tontonoz
2. P. Edwards
3. Johan Auwerx
4. A. Calkin
5. J. Y. Chiang

In Surgery

1. A. Calkin
2. P. Tontonoz
3. G. Svegliati-Baroni
4. P. Edwards
5. Bart Staels
6. Johan Auwerx
7. F. Marra
8. G. Brent

Citations in the corpus

• Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR (2012, background): “Furthermore, the FXR agonist GW4064 repressed hepatic gluconeogenic genes such as glucose-6-phosphatase ( G6pc ) and increased hepatic glycogen synthesis and glycogen content in diabetic mic”
• Gut microbiota-derived metabolites as central regulators in metabolic disorders (2020, background): “103 The synthetic FXR agonist GW4064 improves hyperglycaemic and hyperlipidaemia in mice with diabetes 104 and is able to correct BA dysmetabolism and alleviate liver toxicity in rodents with short bowel.”
• Role of bile acids and bile acid receptors in metabolic regulation. (2009, background): “Interestingly, FXR agonists also reduced the elevated free fatty acid (FFA) levels in insulin-resistant rodents, although the underlying mechanisms remain elusive (21, 364).”
• TGR5-mediated bile acid sensing controls glucose homeostasis. (2009, background): “Instead, FXR-mediated actions of BAs appear mainly to affect liver metabolism by increasing glycogen production (Duran-Sandoval et al., 2005; Ma et al., 2006; Zhang et al., 2006) and decreasing lipogenesis and VLDL production (Watanabe et al.”
• Pleiotropic Roles of Bile Acids in Metabolism (2013, methodology): “Conversely, treatment of diabetic (db/db), obese (ob/ob), or wild-type mice, but not Fxr mice, with bile acids or specific FXR agonists lowered plasma triglyceride, fatty acids, and cholesterol and decreased hepatic lipid levels/steatosis (Watanabe et al., 2004; Zhang et al., 2006).”
• Thyroid hormone regulation of metabolism. (2014, background): “An FXR knockout mouse model resulted in glucose intolerance and insulin insensitivity (280).”
• Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “diabetes, others have not confirmed such functions [141, 142].”
• Energy Metabolism in the Liver (2014, neutral): “Liver-specific overexpression of constitutively active FXR decreases blood glucose (301).”
• Bile Acid Metabolism and Signaling (2013, neutral): “Accumulation of toxic endobiotics xenobiotics causes damage to cells and organs in the tract.”